3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Announces Closing of Convertible Senior Notes Offering
Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Material disclosure
Merger Agreement Between Ligand Pharmaceuticals and XOMA Royalty
Reports First Quarter 2026 Financial Results
Termination of TR-Beta Program - Ligand Pharmaceuticals Notifies Viking
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities